As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a ...

6 years ago
R&D
Pharma

Plug­ging in the last piece to its gene ther­a­py puz­zle, AskBio ac­quires Scot­tish syn­thet­ic pro­mot­er com­pa­ny

6 years ago
Deals
Cell/Gene Tx

Re­gen­eron's pre-filled Eylea sy­ringe makes the FDA cut; Cure­Vac inks pact with Yale

6 years ago
News Briefing

No­var­tis of­floads a late-stage PI3Kẟ rare dis­ease pro­gram in a dis­count deal

6 years ago
Deals
R&D

As ne­go­ti­a­tions with Eng­land la­bor on, Scot­land re­jects rou­tine use of Ver­tex's cys­tic fi­bro­sis drugs

6 years ago
Pharma
FDA+

Pow­er­ful Re­pub­li­can Chuck Grass­ley at­tacks No­var­tis CEO Narasimhan for ‘rep­re­hen­si­ble’ de­ci­sion to hide da­ta

6 years ago
People

Trump's key drug pric­ing ad­vi­sor O'Brien makes HHS ex­it

6 years ago
People

Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK ...

6 years ago
R&D

IBD start­up Lan­dos lands $60M Se­ries B in first test case of Chris Garabe­di­an's lean and mean mod­el at Xon­toge­ny

6 years ago
Financing
Startups

Ques­tions pile up for No­var­tis as sen­a­tors call on FDA to take ac­tion

6 years ago
Cell/Gene Tx
FDA+

Make that 2 new US Big Phar­ma chiefs to­day, as No­var­tis re­makes top team

6 years ago
People
Pharma

How does TDP-43 bog up the brains of ALS, FTLD pa­tients? AC Im­mune en­lists Penn sci­en­tists to find out

6 years ago
Discovery

Ebo­la tri­al stopped ear­ly as Re­gen­eron, Ridge­back ther­a­pies cut death risk; Mer­ck inks deal to test Keytru­da with ...

6 years ago
News Briefing

Shift­ing fo­cus to on­col­o­gy, GSK re­cruits a can­cer vet as new chief of US phar­ma­ceu­ti­cals — adding an­oth­er woman to ...

6 years ago
People

Boehringer fol­lows the pop­u­lar KRAS trail to MD An­der­son — inks new al­liance on 'vir­tu­al' re­search cen­ter

6 years ago
Deals
R&D

Key Ap­ple dig­i­tal health re­searcher set to join the Gates Foun­da­tion — re­port

6 years ago
People
R&D

Bridge­Bio CEO Neil Ku­mar en­gi­neers a deal to reel back Ei­dos shares. Or is he re­al­ly hunt­ing a buy­out?

6 years ago
Deals

Hu­mana takes aim at Mallinck­rodt's 'ill-got­ten' Ac­thar gains in law­suit

6 years ago
Pharma
FDA+

FDA so­lic­its in­dus­try in­put for OND pol­i­cy pri­or­i­ties

6 years ago
FDA+

A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

6 years ago
Financing

Pref­er­en­tial tax poli­cies com­ing for bio­phar­mas set­ting up shop in Shang­hai's newest free trade zone

6 years ago
China

Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

6 years ago
Pharma

US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect ...

6 years ago
Pharma
FDA+

Retrophin paid Mar­tin Shkre­li 'undis­closed sum' to set­tle years­long le­gal dis­putes

6 years ago
People
First page Previous page 923924925926927928929 Next page Last page
A service from the Financial Times